By Tom Ulrich
AtheroMed said it’s raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.
Mercator MedSystems touted European regulatory approvals for a pair of micro-infusion catheters for the treatment of peripheral artery disease.
The San Leandro, Calif.-based medical device company received CE Mark approval in the European Union to market its Cricket and Bullfrog catheters, which are designed to inject therapeutic agents safely through blood vessel walls into deep tissues. The pair of products already have FDA clearance for the U.S. market.
Israel-based Angioslide closed a $6.3 million Series C financing round led by TriVentures, a venture capital fund specializing in medical device technology investments, aimed at expanding its technology in the U.S.
Also participating in the round was return investor’s Viola Partners, Agate and XT Investments, according to the company.
Vascular devices maker TriReme Medical announced a new $18 million financing round in support of the company’s new dilation catheter pipeline and global commercial efforts.
Financing was led by Luminor Capital of Singapore and joined by new Asian investors as well as existing funders, according to a press release.
Medical device maker Trivascular won premarket approval for its Ovation stent graft system, almost precisely 1 year after the FDA granted the device approval under the humanitarian use device pathway.